Segall Bryant & Hamill LLC Buys 17,902 Shares of Encompass Health Co. (NYSE:EHC)

Segall Bryant & Hamill LLC increased its position in shares of Encompass Health Co. (NYSE:EHC - Free Report) by 12.6% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 160,137 shares of the company's stock after purchasing an additional 17,902 shares during the quarter. Segall Bryant & Hamill LLC owned approximately 0.16% of Encompass Health worth $15,476,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in EHC. Vanguard Group Inc. grew its stake in shares of Encompass Health by 1.7% during the first quarter. Vanguard Group Inc. now owns 10,166,147 shares of the company's stock valued at $839,520,000 after purchasing an additional 169,113 shares during the last quarter. O Shaughnessy Asset Management LLC boosted its holdings in Encompass Health by 3.9% in the first quarter. O Shaughnessy Asset Management LLC now owns 4,246 shares of the company's stock valued at $351,000 after acquiring an additional 160 shares during the last quarter. CANADA LIFE ASSURANCE Co increased its position in Encompass Health by 1.0% in the first quarter. CANADA LIFE ASSURANCE Co now owns 61,057 shares of the company's stock worth $5,037,000 after purchasing an additional 578 shares during the period. Healthcare of Ontario Pension Plan Trust Fund bought a new position in shares of Encompass Health in the 1st quarter valued at about $201,000. Finally, Natixis grew its position in shares of Encompass Health by 163.1% during the 1st quarter. Natixis now owns 855 shares of the company's stock worth $71,000 after buying an additional 530 shares during the period. 97.25% of the stock is owned by institutional investors.

Encompass Health Stock Down 0.2 %

Shares of Encompass Health stock opened at $98.90 on Thursday. Encompass Health Co. has a 52-week low of $63.78 and a 52-week high of $104.55. The company has a debt-to-equity ratio of 0.88, a quick ratio of 1.04 and a current ratio of 1.04. The business's 50 day simple moving average is $96.83 and its 200 day simple moving average is $90.63. The firm has a market cap of $9.96 billion, a PE ratio of 23.89, a P/E/G ratio of 1.31 and a beta of 0.88.

Encompass Health (NYSE:EHC - Get Free Report) last released its earnings results on Monday, October 28th. The company reported $1.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.94 by $0.09. The business had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.33 billion. Encompass Health had a return on equity of 17.60% and a net margin of 8.10%. Encompass Health's quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.86 earnings per share. On average, analysts predict that Encompass Health Co. will post 4.29 earnings per share for the current fiscal year.

Encompass Health declared that its board has authorized a share repurchase program on Wednesday, July 24th that allows the company to buyback $500.00 million in outstanding shares. This buyback authorization allows the company to repurchase up to 5.4% of its shares through open market purchases. Shares buyback programs are generally a sign that the company's management believes its shares are undervalued.

Encompass Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Stockholders of record on Thursday, January 2nd will be issued a $0.17 dividend. The ex-dividend date of this dividend is Thursday, January 2nd. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.69%. Encompass Health's payout ratio is 16.43%.

Analysts Set New Price Targets

EHC has been the topic of a number of recent research reports. Truist Financial reaffirmed a "buy" rating and issued a $116.00 price objective (up from $108.00) on shares of Encompass Health in a research note on Wednesday, October 30th. Barclays upped their price objective on Encompass Health from $109.00 to $116.00 and gave the company an "overweight" rating in a report on Tuesday, October 29th. Stephens restated an "overweight" rating and set a $105.00 target price on shares of Encompass Health in a research report on Tuesday, August 6th. Royal Bank of Canada boosted their price target on shares of Encompass Health from $105.00 to $110.00 and gave the company an "outperform" rating in a report on Wednesday, October 30th. Finally, KeyCorp lifted their target price on Encompass Health from $115.00 to $117.00 and gave the stock an "overweight" rating in a report on Tuesday, October 29th. Nine research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $107.11.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.